Study of Pirtobrutinib for immune thrombocytopenia
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called pirtobrutinib for people with immune thrombocytopenia (ITP) who have not responded well to other treatments. The goal is to see if it can help raise your platelet count and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have primary ITP that is not caused by another condition
- You must have tried at least one prior treatment that worked for a while but stopped working or you stopped responding
- Your platelet count must be below 30,000 on two separate tests within 2 weeks before joining
- You cannot have had a blood transfusion or plasmapheresis in the last 2 to 4 weeks
- You cannot have a history of blood clots, heart disease, or certain cancers in the past year
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called budoprutug for people with immune thrombocytopenia (ITP), a condition where your immune system attacks your own platelets, causing low counts. The study aims to see if the drug can safely raise platelet levels and reduce bleeding risk.
This trial tests an oral medication called zanubrutinib to find the best dose for adults newly diagnosed with immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, leading to low counts and bleeding risk. It may offer a new treatment option for those who haven't had any prior therapy.
This trial tests an oral medicine called rilzabrutinib for adults with immune thrombocytopenia (ITP) whose first treatment stopped working or who need steroids long-term. The goal is to see if it helps raise platelet counts and reduce bleeding risk.
This trial tests a combination of two drugs, orelabrutinib and romiplostim, for adults with chronic immune thrombocytopenia (ITP) who have not responded well to or cannot tolerate standard treatments. The goal is to see if this combination can raise platelet levels and reduce bleeding risk.
This Phase 2 study looks at zanubrutinib, a new medication, in people with immune thrombocytopenia (ITP) whose low platelet count has lasted more than 3 months and has not responded to prior steroid and other treatments. It may help raise platelets and reduce bleeding risk when other therapies have not worked.
This study tests pirtobrutinib, a new drug similar to ones you may have already tried, in patients whose B-cell lymphoma (a blood cancer) stopped responding to or caused side effects from prior BTK inhibitor treatments. The goal is to see if this different drug works better for people in your situation.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.